AMENDMENTS TO THE CLAIMS

1. (Currently amended) An intranasal, transdermal, or intradermal dose form ~~pharmaceutical composition~~ comprising 0.5 ng to 20 µg desmopressin and a pharmaceutically acceptable carrier ~~in a dosage form adapted for intranasal, transdermal, or intradermal administration sufficient to establish in~~ which when administered to a patient in accordance with packaged instructions establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per ml plasma/serum to about a maximum of 10.0 picograms desmopressin per ml plasma/serum and ~~to decrease~~ decreases urine production.

2. (Cancelled)

3. (Currently amended) The ~~pharmaceutical composition~~ dose form of claim 1 comprising from about 0.05 µg to about 10 µg desmopressin.

4. (Currently amended) The ~~pharmaceutical composition~~ dose form of claim 1 comprising from about 0.1 µg to about 2 µg desmopressin.

5. (Cancelled)

6. (Currently amended) The ~~pharmaceutical composition~~ dose form of claim 1 ~~in a dosage form adapted for transdermal delivery~~ for application to the skin comprising a patch, gel, cream, ointment, or iontophore.

7. (Currently amended) The ~~pharmaceutical composition~~ dose form of claim 1 ~~adapted for transdermal administration~~ for application to the skin comprising ~~a~~ an intradermal patch.

8. (Cancelled)

9. (Currently amended) The ~~pharmaceutical composition~~ dose form of claim 1 ~~in a dosage form sufficient to establish~~ which establishes in a patient a steady plasma/serum desmopressin

concentration of from about 0.5 picograms desmopressin per ml plasma/serum to about 5.0 picograms desmopressin per ml plasma/serum.

10-26 (Cancelled)

27. (Currently amended) An ~~pharmaceutical~~ intranasal dose form comprising desmopressin and a pharmaceutically acceptable carrier ~~adapted for intranasal administration~~ which when administered intranasally to a patient in accordance with packaged instructions establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per ml plasma/serum to about a maximum of 10.0 picograms desmopressin per ml plasma/serum for a time between four and six hours and decreases urine production.

28. (Currently amended) The ~~composition~~ dose form of claim 27 which establishes in a patient a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per ml plasma/serum to about 5.0 picograms desmopressin per ml plasma/serum.

29. (Currently amended) An intradermal or transdermal pharmaceutical ~~dosage~~ dose form comprising desmopressin and a pharmaceutically acceptable carrier ~~for intranasal or transdermal administration~~ which when administered intradermally or transdermally to a patient establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per ml plasma/serum to about a maximum of 10.0 picograms desmopressin per ml plasma/serum for a time between four and six hours and decreases urine production.

30. (Currently Amended) The ~~dosage~~ dose form of claim 29 which establishes a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per ml plasma/serum to about 5.0 picograms desmopressin per ml plasma/serum.

31. (Currently Amended) The ~~dosage~~ dose form of claim 29 comprising between 0.05 μg and 10 μg desmopressin.

32. (Currently Amended) The ~~dosage~~ dose form of claim 29 ~~adapted for~~ comprising an intradermal ~~administration comprising a~~ patch.

33. (Currently Amended) The ~~dosage~~ dose form of claim 29 ~~adapted for transdermal delivery and~~ comprising a patch, gel, cream, ointment, or iontophore.